scholarly journals Uterine leiomyosarcoma

2021 ◽  
Author(s):  
Henry Knipe ◽  
Pranav Sharma
Keyword(s):  
Uterine Leiomyosarcoma

scholarly journals Impact of Chemotherapy in the Adjuvant Setting of Early Stage Uterine Leiomyosarcoma: A Systematic Review and Updated Meta-Analysis

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1899
Author(s):  
Alessandro Rizzo ◽  
Margherita Nannini ◽  
Annalisa Astolfi ◽  
Valentina Indio ◽  
Pierandrea De Iaco ◽  
...  
Keyword(s):  
Systematic Review ◽  
Recurrence Rate ◽  
Locoregional Recurrence ◽  
Early Stage ◽  
Meta Analysis ◽  
Distant Recurrence ◽  
Uterine Leiomyosarcoma ◽  
Primary Surgery ◽  
Locoregional Recurrence Rate ◽  
Meta Analyses

Background: Although the use of adjuvant chemotherapy (AC) appears to be increasing over the past few years, several clinical trials and previous meta-analyses failed to determine whether AC could improve clinical outcomes in uterine leiomyosarcoma (uLMS). The aim of this systematic review and meta-analysis was to compare AC (with or without radiotherapy) versus observation (obs) after primary surgery in early stage uLMS. Materials and Methods: Randomized controlled (RCTs) and non-randomized studies (NRSs) were retrieved. Outcomes of interest were as follows: distant recurrence rate, locoregional recurrence rate and overall recurrence rate. Results about distant recurrence rate, locoregional recurrence rate and overall recurrence rate were compared by calculating odds ratios (ORs) with 95% confidence intervals (CIs); ORs were combined with Mantel–Haenszel method. Results: Nine studies were included in the analysis, involving 545 patients (AC: 252, obs: 293). Compared with obs, AC did not reduce locoregional and distant recurrence rate, with a pooled OR of 1.36 and 0.63, respectively. Similarly, administration of AC did not decrease overall recurrence rate in comparison to obs. Conclusion: According to our results, AC (with or without radiotherapy) did not decrease recurrence rate in early stage uLMS; thus, the role of AC in this setting remains unclear.

Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: A Turkish Uterine Sarcoma Group Study-003

2021 ◽  
pp. 100712
Author(s):  
Ali Ayhan ◽  
Kemal Gungorduk ◽  
Ghanim Khatib ◽  
Zeliha Fırat Cüylan ◽  
Nurettin Boran ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Uterine Sarcoma ◽  
Survival Outcomes ◽  
Uterine Leiomyosarcoma

Proposing the 3‐tier staging system for improving prognostication in Stage I uterine leiomyosarcoma

2020 ◽  
Author(s):  
Koji Matsuo ◽  
Shinya Matsuzaki ◽  
David J. Nusbaum ◽  
Yoshikazu Nagase ◽  
Elizabeth Y. Hur ◽  
...  
Keyword(s):  
Staging System ◽  
Stage I ◽  
Uterine Leiomyosarcoma

Diffusion-Weighted Imaging for Differentiating Uterine Leiomyosarcoma From Degenerated Leiomyoma

2017 ◽  
Vol 41 (4) ◽  
pp. 599-606 ◽  
Author(s):  
Hai Ming Li ◽  
Jia Liu ◽  
Jin Wei Qiang ◽  
Hao Zhang ◽  
Guo Fu Zhang ◽  
...  
Keyword(s):  
Diffusion Weighted Imaging ◽  
Uterine Leiomyosarcoma ◽  
Diffusion Weighted

Long-Term Survival in a Patient With Abdominal Sarcomatosis From Uterine Leiomyosarcoma: Role of Repeated Laparoscopic Surgery in Treatment and Follow-Up

2016 ◽  
Vol 23 (6) ◽  
pp. 1003-1008 ◽  
Author(s):  
Antonio Macciò ◽  
Paraskevas Kotsonis ◽  
Giacomo Chiappe ◽  
Luca Melis ◽  
Fausto Zamboni ◽  
...  
Keyword(s):  
Laparoscopic Surgery ◽  
Uterine Leiomyosarcoma ◽  
Term Survival ◽  
Long Term Survival

Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma

2021 ◽  
Vol 162 ◽  
pp. S280-S281 ◽  
Author(s):  
Shinya Matsuzaki ◽  
Satoko Matsuzaki ◽  
Erica Chang ◽  
Maya Yasukawa ◽  
Lynda Roman ◽  
...  
Keyword(s):  
Intraperitoneal Chemotherapy ◽  
Hyperthermic Intraperitoneal Chemotherapy ◽  
Oncologic Outcomes ◽  
Uterine Leiomyosarcoma

scholarly journals Oral Abstract

2016 ◽  
Author(s):  
Dharma Ram
Keyword(s):  
Survival Data ◽  
Eligible Patient ◽  
Stage Iv ◽  
Endometrial Stromal Sarcoma ◽  
Uterine Sarcoma ◽  
Low Grade ◽  
Uterine Leiomyosarcoma ◽  
High Grade ◽  
Lost To Follow Up

Introduction: Uterine sarcoma accounts for nearly 3% of all uterine malignancies. They have 4 major pathology includes endometrial stromal sarcoma high grade, ESS low grade, uterine leiomyosarcoma (uLMS) and undifferentiated uterine sarcoma (UUS). Recent WHO classification 2014, recognizes low grade ESS and high grade ESS as distinct entity. They differ from endometrial carcinoma in their aggressive nature and poor prognosis. We review our database and found total 44 eligible patient treated at our institute. Materials and Methods: Its retrospective analysis of computer based database of our institute from January 2009 to December 2015. We analyzed demographic, pathological, treatment and survival data. Results: Total 44 patient treated for uterine sarcoma at our institute. Among these 16 were operated at our institute during study period. Here we reporting results of operated patients at our institute. The histological diagnosis LMS (5/16), ESS-L (4/16), MMMT (3/16), UUS (3/16) and ESS-H (1/16). Stage distribution was stage I, (6/16) stage II, (5/16) stage III, (3/16) stage IV, (0/16) and unknown stage (2/16). Two patients underwent completion surgery for outside myomectomy. The adjuvant treatment was CT in 3/16, CT with RT in 7/16, HT in 4/16 and one lost to follow up with one was put on observation. Median follow up is 30 month with 14 patients alive and one lost to follow up. At last follow up 4 patients alive with metastatic disease and 10 patients alive with no evidence of disease. Conclusion: Uterine sarcoma are uncommon disease with

Sign in / Sign up

Export Citation Format

Share Document